Journal of Financial and Quantitative Analysis Vol. 60 No. 7 2025
Information Disclosure and Peer Innovation: Evidence from Mandatory Reporting of Clinical Trials
Abstract
We document significant increases in the suspension of ongoing drug projects following the passage of the Food and Drug Administration Amendments Act of 2007 (FDAAA), which mandates that pharmaceutical companies publicly disclose detailed clinical study results. Our results suggest a causal interpretation through difference-in-differences analyses that exploit variations in pre-FDAAA information environments. We also show evidence that fewer new projects are initiated after the FDAAA. Drug developers’ learning from peer failures is the primary mechanism, further amplified by financial constraints. We also examine the consequences of enhanced information disclosure, including changes in firm investment efficiency, drug quality, and disease morbidity.
- DOI
- 10.1017/s002210902400084x
- Volume
- 60
- Issue
- 7
- Pages
- 3267-3310
- Language
- en
- Sources
- openalex crossref